582 related articles for article (PubMed ID: 26590293)
1. Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial.
Ng KH; Shestakovska O; Connolly SJ; Eikelboom JW; Avezum A; Diaz R; Lanas F; Yusuf S; Hart RG
Age Ageing; 2016 Jan; 45(1):77-83. PubMed ID: 26590293
[TBL] [Abstract][Full Text] [Related]
2. Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial.
Flaker GC; Eikelboom JW; Shestakovska O; Connolly SJ; Kaatz S; Budaj A; Husted S; Yusuf S; Lip GY; Hart RG
Stroke; 2012 Dec; 43(12):3291-7. PubMed ID: 23033347
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
[TBL] [Abstract][Full Text] [Related]
4. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.
Diener HC; Eikelboom J; Connolly SJ; Joyner CD; Hart RG; Lip GY; O'Donnell M; Hohnloser SH; Hankey GJ; Shestakovska O; Yusuf S;
Lancet Neurol; 2012 Mar; 11(3):225-31. PubMed ID: 22305462
[TBL] [Abstract][Full Text] [Related]
5. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
Yates SW
Hosp Pract (1995); 2011 Oct; 39(4):7-16. PubMed ID: 22056819
[TBL] [Abstract][Full Text] [Related]
6. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease.
Eikelboom JW; Connolly SJ; Gao P; Paolasso E; De Caterina R; Husted S; O'Donnell M; Yusuf S; Hart RG
J Stroke Cerebrovasc Dis; 2012 Aug; 21(6):429-35. PubMed ID: 22818021
[TBL] [Abstract][Full Text] [Related]
7. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation Patients.
Lip GY; Lanitis T; Mardekian J; Kongnakorn T; Phatak H; Dorian P
Stroke; 2015 Oct; 46(10):2830-7. PubMed ID: 26316345
[TBL] [Abstract][Full Text] [Related]
9. Risk/Benefit Tradeoff of Antithrombotic Therapy in Patients With Atrial Fibrillation Early and Late After an Acute Coronary Syndrome or Percutaneous Coronary Intervention: Insights From AUGUSTUS.
Alexander JH; Wojdyla D; Vora AN; Thomas L; Granger CB; Goodman SG; Aronson R; Windecker S; Mehran R; Lopes RD
Circulation; 2020 May; 141(20):1618-1627. PubMed ID: 32223444
[TBL] [Abstract][Full Text] [Related]
10. Apixaban in patients with atrial fibrillation.
Connolly SJ; Eikelboom J; Joyner C; Diener HC; Hart R; Golitsyn S; Flaker G; Avezum A; Hohnloser SH; Diaz R; Talajic M; Zhu J; Pais P; Budaj A; Parkhomenko A; Jansky P; Commerford P; Tan RS; Sim KH; Lewis BS; Van Mieghem W; Lip GY; Kim JH; Lanas-Zanetti F; Gonzalez-Hermosillo A; Dans AL; Munawar M; O'Donnell M; Lawrence J; Lewis G; Afzal R; Yusuf S;
N Engl J Med; 2011 Mar; 364(9):806-17. PubMed ID: 21309657
[TBL] [Abstract][Full Text] [Related]
11. Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study.
Lip GY; Eikelboom J; Yusuf S; Shestakovska O; Hart RG; Connolly S;
Stroke; 2014 Jul; 45(7):2127-30. PubMed ID: 24916911
[TBL] [Abstract][Full Text] [Related]
12. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial.
van Nieuwenhuizen KM; van der Worp HB; Algra A; Kappelle LJ; Rinkel GJ; van Gelder IC; Schutgens RE; Klijn CJ;
Trials; 2015 Sep; 16():393. PubMed ID: 26340977
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of AVERROES: apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment.
Eikelboom JW; O'Donnell M; Yusuf S; Diaz R; Flaker G; Hart R; Hohnloser S; Joyner C; Lawrence J; Pais P; Pogue J; Synhorst D; Connolly SJ
Am Heart J; 2010 Mar; 159(3):348-353.e1. PubMed ID: 20211294
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial.
Hu PT; Lopes RD; Stevens SR; Wallentin L; Thomas L; Alexander JH; Hanna M; Lewis BS; Verheugt FW; Granger CB; Jones WS
J Am Heart Assoc; 2017 Jan; 6(1):. PubMed ID: 28096100
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial.
Coppens M; Synhorst D; Eikelboom JW; Yusuf S; Shestakovska O; Connolly SJ
Eur Heart J; 2014 Jul; 35(28):1856-63. PubMed ID: 24569032
[TBL] [Abstract][Full Text] [Related]
16. Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium.
Kongnakorn T; Lanitis T; Lieven A; Thijs V; Marbaix S
Clin Drug Investig; 2014 Oct; 34(10):709-21. PubMed ID: 25164005
[TBL] [Abstract][Full Text] [Related]
17. Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study.
Lip GY; Connolly S; Yusuf S; Shestakovska O; Flaker G; Hart R; Lanas F; Xavier D; Eikelboom J;
Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):31-8. PubMed ID: 23390125
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation in Saudi Arabia.
Hersi AS; Osenenko KM; Kherraf SA; Aziz AA; Sambrook RJ
Ann Saudi Med; 2019; 39(4):265-278. PubMed ID: 31381381
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.
Hohnloser SH; Fudim M; Alexander JH; Wojdyla DM; Ezekowitz JA; Hanna M; Atar D; Hijazi Z; Bahit MC; Al-Khatib SM; Lopez-Sendon JL; Wallentin L; Granger CB; Lopes RD
Circulation; 2019 May; 139(20):2292-2300. PubMed ID: 30773022
[TBL] [Abstract][Full Text] [Related]
20. Cost Effectiveness of Apixaban versus Warfarin or Aspirin for Stroke Prevention in Patients with Atrial Fibrillation: A Greek Perspective.
Athanasakis K; Boubouchairopoulou N; Karampli E; Tarantilis F; Savvari P; Bilitou A; Kyriopoulos J
Am J Cardiovasc Drugs; 2017 Apr; 17(2):123-133. PubMed ID: 27882517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
